The scope of DYNAMO is to combine the two fields of business continuity management (BCM) and cyber threat intelligence (CTI) to generate a situational awareness picture for decision support across all stages of the resilience cycle (prepare, prevent, protect, response, recover). Professionals of different backgrounds will work together with end-users to develop, refine and combine selected tools into a single platform. In alignment to end-user needs, human factors, high ethical standards and societal impacts, DYNAMO includes the following goals: Resilience assessment as basis for BCM - An assessment with different levels of detail offers with varying existent data a fast or detailed evaluation of the investigated sector and helps to identify critical processes. - End-user data will be integrated to measure determined performance targets. With respect to the functional description, AI-based approaches will be used for a deeper understanding and potential self-learning of the interconnected process. - The results generate knowledge concerning susceptibility and vulnerability of the investigated sector. - The solutions support the BCM with respect to the five resilience phases. Leveraging CTI - CTI will be improved with respect to existing solutions (H2020 ECHO, PANACEA). - The H2020 Early Warning System (EWS) will be extended and integrated. A Malware Information Sharing Platform (MISP) will be used to raise the situational awareness between different security actors. - The CTI approach deliver data that will be integrated into the resilience and BCM approach. The use of AI will support the development. Solutions will be integrated with the Cyber Knowledge Graph to visualize the analysis of threat intelligence. The DYNAMO platform will be able to collect organization’s skills data, elaborate and create custom tailored organisational training to improve organisational resilience which will be demonstrated within three different (cross-)sectoral use-cases.

PANACEA will deliver people-centric cybersecurity solutions in healthcare. The Partners will execute on a leanly-orchestrated research workplan, which envisages continuous involvement of the end-user Partners at three European health care centres, including also devices utilised in remote care & homecare settings. Ultimately, PANACEA delivers two toolkits for cyber security assessment and preparedness of Healthcare ICT infrastructures and connected devices: the Solution Toolkit and the Delivery Toolkit. The first one comprisesfour technological tools (for dynamic risk assessment & mitigation, secure information sharing, security-by-design & certification, identification & authentication) and three organisational tools (for training & education, resilience governance, secure behaviours nudging). The second one, specifically supporting adoption of the solution toolkit, comprises two tools (methodology to evaluate the ROI of cybersecurity interventions, guidelines to adopt the solution toolkit and implement other ex-ante mitigation actions). The toolkit will benefit from ninePANACEA ambitious research goals, achieved by moving beyond the current state of the art in the strategic areas of dynamic risk assessment & mitigation (threat modelling, attack modelling, response management, visual analytics), blockchain for secure information sharing, identification/authentication (cryptographic authentication protocols, biometric recognition/digital identity, IoMT identification), secure behaviours decision models and influencers. Impact creation will be supported by designing and executing on an effective communication, dissemination and exploitation strategy involving all partners, from project onset. The PANACEA Consortium is committed, competent and complementary. The Consortium is led by a private hospital, supported by 3 research organisations, 3 large enterprises, 5 SMEs. Severalend-user scenarios, developed in Italy, Crete and Ireland, will provide a solid test-bed.

The vision of TERMINET is to provide a novel next generation reference architecture based on cutting-edge technologies such as SDN, multiple-access edge computing, and virtualisation for next generation IoT, while introducing new, intelligent IoT devices for low-latency, market-oriented use cases. TERMINET’s primary intention is to bring (more efficient and accurate) decisions to the point of interest to better serve the final user targeting at applying distributed AI at the edge by using accelerated hardware and sophisticated software to support local AI model training using federated learning. Our solution aspires to reduce the complexity of the connecting vast number of heterogeneous devices through a flexible SDN-enabled middleware layer. It also aims to design, develop, and integrate novel, intelligent IoT devices such as smart glasses, haptic devices, energy harvesting modules, smart animal monitoring collars, AR/VR environments, and autonomous drones, to support new market-oriented use cases. Great expectation of the proposal is to foster AR/VR contextual computing by demonstrating applicable results in realistic use cases by using cutting-edge IoT-enabled AR/VR applications. By designing and implementing an IoT-driven decentralised and distributed blockchain framework within manufacturing, TERMINET aims to support maintenance and supply chain optimisation. Our solution intends to apply a vertical security by design methodology by meeting the privacy-preserving and trust requirements of the NG-IoT architecture. To foster standardisation activities for the IoT ecosystem, TERMINET will provide novel disruptive business models. For the evaluation of its wide applicability, TERMINET will validate and demonstrate six proof-of-concept, realistic use cases in compelling IoT domains such as the energy, smart buildings, smart farming, healthcare, and manufacturing.

Survivors of AYA cancer are at risk of treatment-related mortality and morbidity (late effects). The impact on the quality of life (QoL) of AYA cancer survivors and their families, as well as the societal and economic burdens, is significant. However, these impacts can be prevented or reduced by long-term, systematic screening and follow-up (Survivorship Care), which enables the early detection of treatable late effects and timely interventions to preserve health, increase empowerment, manage chronic conditions and improve QoL. PanCare4AYA will improve Survivorship Care for AYA cancer survivors across Europe by developing an international clinical guideline for screening and follow-up. This guideline will be implemented via a novel person-centred screening programme (AYA Cancer Survivor Screen). An implementation study involving 1,000 AYA cancer survivors in 11 European countries (Croatia, Czech Republic, France, Germany, Italy, Lithuania, Netherlands, Norway, Sweden, Switzerland, United Kingdom) will be conducted to test the AYA Cancer Survivor Screen programme, including peer support. The study will look at effectiveness (empowerment, mental health, psychosocial functioning and other QoL-related outcomes), healthcare delivery and screening-related health, experiences of AYA cancer survivors and HCPs with implementing the state-of-the-art screening programme within a range of different healthcare settings, and feasibility. Innovative digital tools will be used in France, Italy, Lithuania and Netherlands. Ensuring the scalability of the AYA Cancer Survivor Screen programme is crucial for achieving enduring, real-world improvements to Survivorship Care for AYA cancer survivors. Therefore, the project includes the assessment of barriers and facilitators for the screening programme and development of freely available materials to support sustainable maintenance and scale-up of AYA Cancer Survivor Screen in additional clinics in future. This action is part of the Cancer Mission cluster of projects on “Quality of life (AYA)”.

MULTISCOPE introduces a revolutionary photonic technology that represents a significant advancement in the field of optical diagnostics and therapy. Our approach is based on cutting-edge research into pulse propagation within nonlinear complex structures. We are developing an endoscopic device that seamlessly combines optical biopsy and cold atmospheric plasma treatment. This dual-functionality device harnesses the spatiotemporal control of powerful light in multimode fibers, which were previously overlooked due to concerns about excessive light destructuring. We leverage the remarkable progress in the development of the latest optical fibers and in the precise control of light within multimode guides, enabling us to harness the power of plasma, the fourth state of matter. Initially, our focus is on gastrointestinal (GI) endoscopy, but our ultimate goal is to extend this technology to all areas of medical diagnostics where there is a pressing need for reliable tools for "optical biopsy" and "instant pathology." These tools are crucial for real-time diagnosis but have not yet reached the level of trustworthiness required for widespread use. Endoscopy is a vital tool for diagnosing and treating GI disorders, offering a safe and effective approach. However, the current standard of care still relies on histopathology for conclusive cancer diagnosis. This leads to significant delays in initiating treatment and incurs high costs. Our project is set to transform this landscape by bringing to life the long-anticipated concept of real-time, in-vivo optical diagnosis, often referred to as "optical biopsy". Our groundbreaking approach seamlessly integrates endoscopic capabilities with cold atmospheric plasma therapy, which employs controlled plasma jets to precisely target and eliminate cancer cells by inducing cellular apoptosis. By combining plasma therapy with optical biopsy, we not only provide real-time diagnosis but also offer immediate therapeutic intervention.